Patients with advanced and metastatic renal cell carcinoma treated with targeted tgerapy in the Czech Republic: twenty cancer centres, six agnets, one database

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000368" target="_blank" >RIV/00209805:_____/12:#0000368 - isvavai.cz</a>

Výsledek na webu

<a href="http://link.springer.com.proxy.mzk.cz/article/10.1007%2Fs12032-012-0286-9" target="_blank" >http://link.springer.com.proxy.mzk.cz/article/10.1007%2Fs12032-012-0286-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12032-012-0286-9" target="_blank" >10.1007/s12032-012-0286-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Patients with advanced and metastatic renal cell carcinoma treated with targeted tgerapy in the Czech Republic: twenty cancer centres, six agnets, one database

Popis výsledku v původním jazyce

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-base

Název v anglickém jazyce

Patients with advanced and metastatic renal cell carcinoma treated with targeted tgerapy in the Czech Republic: twenty cancer centres, six agnets, one database

Popis výsledku anglicky

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-base

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medical oncology

ISSN

1357-0560

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

3314-3320

Kód UT WoS článku

000311513800045

EID výsledku v databázi Scopus

—